Q2 EPS Forecast for Milestone Pharmaceuticals Cut by Analyst

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings estimates for shares of Milestone Pharmaceuticals in a research note issued on Wednesday, May 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.19) for the quarter, down from their prior forecast of ($0.18). The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.78) EPS, FY2027 earnings at ($0.79) EPS and FY2029 earnings at $1.08 EPS.

MIST has been the topic of a number of other research reports. Zacks Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday. Raymond James Financial assumed coverage on shares of Milestone Pharmaceuticals in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 target price for the company. Finally, Wells Fargo & Company dropped their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.25.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock opened at $1.46 on Tuesday. The firm has a market cap of $181.77 million, a PE ratio of -2.15 and a beta of 1.04. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. The company’s fifty day simple moving average is $1.70 and its two-hundred day simple moving average is $1.92.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $30.12 million.

Insider Activity at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the sale, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Propel Bio Management LLC lifted its position in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after purchasing an additional 3,333,333 shares during the period. Orbimed Advisors LLC purchased a new position in Milestone Pharmaceuticals during the 3rd quarter valued at about $6,444,000. Marshall Wace LLP lifted its position in Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after acquiring an additional 1,231,793 shares during the period. Pathstone Holdings LLC purchased a new position in Milestone Pharmaceuticals during the 3rd quarter valued at about $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the 3rd quarter valued at about $1,333,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.